Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APONVIE
- Development stage
- Approved
- Lead developer
- Heron Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
APONVIE (aprepitant) is an intravenous injectable emulsion formulation of the substance P/neurokinin-1 (NK1) receptor antagonist, developed by Heron Therapeutics. It is specifically indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Delivered as a 30-second intravenous infusion, APONVIE provides rapid achievement of therapeutic drug levels and is bioequivalent to oral aprepitant. It utilizes a proprietary surfactant-free, polysorbate 80-free formulation, which is the same as Heron's CINVANTI (indicated for chemotherapy-induced nausea and vomiting). By blocking the NK1 receptor, it inhibits the binding of substance P, a key mediator in the emetic pathway, particularly in the area postrema of the brain.
- Brand names
- APONVIE
- Other names
- aprepitant injectable emulsion
02
Targets
TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on APONVIE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APONVIE.